Skip to Main Content

Advertisement

Skip Nav Destination

Issues

TOP READS

J Immunol (2023) 211 (9): 1253.

PILLARS OF IMMUNOLOGY

J Immunol (2023) 211 (9): 1255–1256.

BRIEF REVIEWS

J Immunol (2023) 211 (9): 1257–1265.
J Immunol (2023) 211 (9): 1266–1275.
J Immunol (2023) 211 (9): 1276–1285.

ALLERGY AND OTHER HYPERSENSITIVITIES

J Immunol (2023) 211 (9): 1287–1297.

  • Our results suggest a potential risk factor of SEB in food allergy.

  • Coexposure to SEB could aggravate hypothermia and diarrhea induced by OVA allergy.

  • The dose of SEB plays a dominant role in the direction of Th cell differentiation.

ANTIGEN RECOGNITION AND RESPONSES

J Immunol (2023) 211 (9): 1298–1307.

  • Tapasin alters HLA class I peptide binding preferences at peptide C-termini.

  • Tapasin-independent assembly expands affinity range of peptide–HLA class I binding.

AUTOIMMUNITY

J Immunol (2023) 211 (9): 1308–1319.

  • Reduction of IRF5 expression after disease onset reduces disease in murine lupus.

  • Reduction of IRF5 expression impacts systemic and end-organ pathogenic pathways.

J Immunol (2023) 211 (9): 1320–1331.

  • Neonatal, but not adult, immunization with group A Streptococcus delays T1D in NOD mice.

  • Immunization enriches B1 cells reactive to apoptotic β cells in the pancreas.

  • These expanded B1 cells delay T1D progression by multiple immunological mechanisms.

CLINICAL AND HUMAN IMMUNOLOGY

J Immunol (2023) 211 (9): 1332–1339.

  • Ab-secreting B cell expansion is shown in the cerebrospinal fluid of pediatric NMDAR-AE patients.

  • VH2 overuse in a treatment-refractory pediatric NMDAR-AE case is described.

  • A CDR3 motif of NR1-binding VH2-70+ B cells is identified.

IMMUNE REGULATION

J Immunol (2023) 211 (9): 1340–1347.

  • Jagged1 is an RBP-J target, and TNF activates the RBP-J/Jagged1 axis in macrophages.

  • TNF-induced Jagged1 is a feedback inhibitor of inflammatory osteoclastogenesis.

  • RANKL does not induce Jagged1, which does not affect RANKL-induced osteoclastogenesis.

J Immunol (2023) 211 (9): 1348–1358.

  • TRPML1-derived lysosomal calcium regulates mitochondrial organization and fitness.

  • Loss of the lysosomal calcium channel TRPML1 leads to mitochondrial dysfunction.

  • TRPML1 activity modulates autophagy induction, a prerequisite for mitophagy.

J Immunol (2023) 211 (9): 1359–1366.

  • Foxp3 TSDR demethylation is governed by autocrine C3ar1/C5ar1 signaling in Tregs.

  • Treg generation under in vivo conditions is required for TSDR demethylation.

J Immunol (2023) 211 (9): 1367–1375.

  • CD160 is intrinsically required for virus-induced CD8+ T cell memory formation.

  • 4-1BB is a major downstream target of CD160 in regulating CD8+ T cell activation.

IMMUNE SYSTEM DEVELOPMENT

J Immunol (2023) 211 (9): 1376–1384.

  • Signaling and metabolic pathways differ in thymic versus liver and spleen iNKT1 cells.

  • TGF-β promotes the postselection maturation of thymic iNKT1 cells.

  • TGF-β controls TGF-β and cytokine signaling gene signatures in thymic iNKT1 cells.

INFECTIOUS DISEASE AND HOST RESPONSE

J Immunol (2023) 211 (9): 1385–1396.

  • ManLAM suppresses productive activation of human CD4+ T cells.

  • ManLAM can be acquired by CD4+ T cells from BCG-infected monocytes in cocultures.

  • ManLAM disrupts the integrity of the CD4+ T cell–macrophage immunological synapse.

J Immunol (2023) 211 (9): 1397–1405.

  • IFN-γ delays Pneumocystis clearance by suppressing the pulmonary Th17 response.

  • IFN-γ limits PcP-related immunopathogenesis by restraining lung inflammation.

INNATE IMMUNITY AND INFLAMMATION

J Immunol (2023) 211 (9): 1406–1417.

  • SLC25A23 can interfere with the binding of Trim31 to MAVS.

  • SLC25A23 attenuates type I IFN antiviral immunity.

  • SLC25A23 knockdown mice are more resistant to RNA virus infection.

TUMOR IMMUNOLOGY

J Immunol (2023) 211 (9): 1418–1425.

  • DRD1 is higher expressed on ILC2s in the TME than in the lung.

  • DRD1 deficiency curtails tumor growth via boosting ILC2 responses in mice.

  • Activating the DRD1 signal impairs the ILC2 response, along with bluntness of tumor control.

NOVEL IMMUNOLOGICAL METHODS

J Immunol (2023) 211 (9): 1426–1437.

  • To our knowledge, we established a successful novel humanized GVL model system.

  • AML induced T cell depletion and T cell exhaustion in the humanized GVL model.

  • Triple blockade of PD-1, TIGIT, and TIM-3 effectively reduced leukemia burden.

Close Modal

or Create an Account

Close Modal
Close Modal